MBX logo

MBX MBX Biosciences, Inc. Common Stock

NASDAQ Global Select · Biotechnology · Healthcare

$49.55
-3.86 (-7.23%)

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for indiv…

Market Cap: $2.46Bmbxbio.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
—
60d
50
2 mentions
—
90d
58
7 mentions
—
news: 7

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 0Sell 0Strong Sell 0
Avg price target$97.67+97.1%
Low $84Median $88High $150
Current Consensus

Revenue

$0.00
$0.00
Mar 2023Sep 2026

Analyst Estimates

FY2025
$-2.47
$-2.65–$-2.33
6 analysts
FY2026
$-3.43
$-3.78–$-3.12
7 analysts
FY2027
$-4.22
$-4.52–$-3.99
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Steve Hoerter
Sector
Healthcare
Industry
Biotechnology
Employees
63
Beta
0.10
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
52.52
mbxbio.com